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Abstract
Background: The incidence of nontuberculous mycobacterial (NTM) pulmonary disease caused by Mycobacterium
avium complex (MAC) in apparently immune-competent people is increasing worldwide. We performed a systematic
review of the published literature on five-year all-cause mortality in patients with MAC lung disease, and pooled the
mortality rates to give an overall estimate of five-year mortality from these studies.
Methods: We systematically reviewed the literature up to 1st August 2017 using PubMed® and ProQuest Dialog™ to
search Medline® and Embase® databases, respectively. Eligible studies contained > 10 patients with MAC, and numerical
five-year mortality data or a treatment evaluation for this patient group. Mortality data were extracted and analysed to
determine a pooled estimate of all-cause mortality.
Results: Fourteen of 1035 identified studies, comprising 17 data sets with data from a total of 9035 patients, were eligible.
The pooled estimate of five-year all-cause mortality was 27% (95% CI 21.3–37.8%). A high degree of heterogeneity was
observed (I2 = 96%). The mortality in the data sets varied between 10 and 48%. Studies predominantly including patients
with cavitary disease or greater comorbidity reported a higher risk of death. Patients in Asian studies tended to have a
lower mortality risk. Predictors of mortality consistent across studies included male sex, presence of comorbidities and
advanced patient age.
Conclusions: Despite high heterogeneity, most studies in patients with MAC pulmonary disease document a five-year
all-cause mortality exceeding 25%, indicating poor prognosis. These findings emphasise the need for more effective
management and additional prospective mortality data collection.
Keywords: Infectious disease, Nontuberculous mycobacteria, NTM, Survival outcome
Background
Nontuberculous mycobacteria (NTM) are ubiquitous en-
vironmental bacteria, present in soil and water sources
[1]. NTM are thought of as opportunistic pathogens,
with disseminated NTM disease being seen in patients
with systemic impaired immunity (e.g. HIV) [2, 3]. Inter-
est in NTM pulmonary disease (NTM-PD) is increasing
due to its growing prevalence in non-HIV populations
[2]. It can occur in the context of lung disease caused
by, for example, bronchiectasis, chronic obstructive
pulmonary disease (COPD) or cystic fibrosis (CF), and
also in people with apparently normal lungs [2, 3].
NTM-PD symptoms are nonspecific and variable; pa-
tients may present with both respiratory and systemic
complaints, which may relate to underlying lung disease
[2]. NTM-PD usually manifests radiologically with fibro-
cavitary or nodular/bronchiectatic forms [2]. NTM-PD
diagnosis is generally made when the American Thoracic
Society/Infectious Diseases Society of America (ATS/
IDSA) diagnostic criteria are met [2].
MAC is considered to be the most common cause of
NTM-PD [4]. It comprises various mycobacterial
species, including M. intracellulare, M. avium (which
has four subspecies), and several other less frequently
isolated species including M. chimaera [5, 6]. The
* Correspondence: Wouter.Hoefsloot@radboudumc.nl
4Department of pulmonary diseases, Geert Grooteplein Zuid 10, 6525, GA,
Nijmegen, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Diel et al. BMC Infectious Diseases  (2018) 18:206 
https://doi.org/10.1186/s12879-018-3113-x
decision to treat MAC infections depends on the pa-
tient’s health status and risk of disease progression. Ac-
cording to published recommendations, patients with
nodular/bronchiectatic MAC disease should be offered a
combination of macrolide (clarithromycin or azithromy-
cin), rifampin or rifabutin, and ethambutol [2, 4]. In
patients with fibrocavitary or severe nodular/bronchiec-
tatic disease, addition of parenteral aminoglycosides may
be considered [2]. Many are, however, refractory to first-
line therapy and do not achieve sustained culture con-
version [7]. Effective treatment choices for these people
are few, essentially limited to intensification or modifica-
tion of the first-line regimen or surgical resection of
infected lung tissue [7].
MAC lung disease natural history and long-term out-
comes are poorly documented, particularly at the popu-
lation level [8]. A retrospective chart review of patients
from Oregon, USA with respiratory NTM isolates found
that the median time to death was 3.6 (range 0–7.7)
years for cases meeting ATS/IDSA diagnostic criteria [2]
and 3.7 (range 0.0–8.6) years for those who did not (p =
0.63). Here, 55% of the cases and 61% of the non-cases
died during the follow-up period (2007–2014), with no
statistically significant difference in five-year mortality
between cases and non-cases [8].
A previous systematic review of reported treatment out-
comes in patients with MAC lung disease, based on a
pooled analysis of 28 studies carried out between 1977
and 2004, found overall mortality to be 17% (95% confi-
dence interval [CI] 15–18%) [9]. However, this mainly in-
cluded studies of short duration, and the calculated
mortality rates did not account for different patient follow
up-times within the studies [9]. Thus, it is not possible to
draw firm conclusions regarding longer-term mortality
from this report. Another recent systematic review sought
to examine comorbidities, health-related quality of life
and mortality associated with NTM disease in various pa-
tient populations [10]. Again, variable follow-up times in
the included studies (30 days to over 10 years) limited the
understanding of long-term mortality. Moreover, no dif-
ferentiation was made between NTM-PD and NTM-non-
PD, or different NTM species [10].
We therefore sought to systematically review the pub-
lished literature for data on long-term mortality in pa-
tients with MAC lung disease, pool five-year mortality
results to gain an estimate of overall five-year all-cause
mortality in these patients, and explore study character-
istics that may have contributed to variability in mortal-
ity reports or predict patient outcome.
Methods
Data sources
Database searches were carried out in Medline® and
Embase®, using PubMed® and ProQuest Dialog™ search
tools, respectively, with a cut-off of 1st August 2017, ac-
cording to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [11].
English language studies were selected. The search
strategy applied to each database is described in the
Additional file 1. Duplicates, case reports, nonclinical
and animal studies were excluded, as were conference
abstracts, newspaper articles, notes, news, biography,
conference reviews, errata and lectures.
Study selection
Relevant studies were independently selected by two
reviewing authors (WH and RD), who screened the
article title and abstract initially, and then went on to re-
view the article full text as needed. Studies were in-
cluded if they reported five-year all-cause mortality in
cohorts of patients with MAC lung disease, or NTM-PD
cohorts where the majority of patients (≥75%) had MAC
lung disease. No restrictions were made regarding study
design, patient subpopulation, or data collection (pro-
spective or retrospective). Studies with fewer than ten
patients were excluded because of uncertainty about val-
idity of the presented data and outcome in smaller
studies.
Data extraction
The following data were extracted from the selected
publications: five-year all-cause mortality, proportion of
MAC-attributable deaths, factors predicting all-cause
mortality, all-cause mortality in patients with fibrocavi-
tary or nodular/bronchiectatic disease, and MAC-related
mortality in patients with fibrocavitary or nodular/
bronchiectatic disease.
Statistical analysis
Heterogeneity in reported mortality rates was quantified
in terms of the Q- and I2-statistics. The Q-statistic is
based on the chi-squared test and assesses deviation be-
tween individual study effect and the pooled effect across
studies. A large Q-value relative to its degree of freedom
provides evidence of heterogeneity of the measured out-
come (variation in outcome estimates beyond chance).
The I2-statistic describes the percentage of the variability
in outcome estimates due to heterogeneity rather than
sampling error (chance). Five-year mortality rates were
pooled across the studies using a random-effects model.
The analysis was performed using Review Manager (Rev-
Man version 5.3. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014 software).
Results
Study selection and identified studies
The PubMed® search of Medline® returned 845 studies,
and the ProQuest Dialog search (using Embase® and
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Medline® databases) returned 1311 studies. Following
comparison of the results and de-duplication, 1035 pub-
lications remained. This selection was screened by title,
abstract content and full text if needed. Following the
exclusion criteria stated in the Methods section, 14 stud-
ies comprising 17 data sets with data from 9035 patients
remained for analysis. A flowchart depicting this selec-
tion process is shown in Fig. 1.
The identified studies and their key characteristics are
listed in Table 1 [12–25]. Among these 17 data sets, nine
were retrospective medical chart review studies [12–19],
five were retrospective population registry analyses
[20–23] and three were from prospective, randomised
studies [24, 25]. Three studies included data from two
cohorts of patients with MAC lung disease, and these are
considered separately for the purposes of this analysis [19,
23, 25]. The number of patients with MAC in the studies
ranged from 45 to 5543. Two studies examined patients
with other NTM infections (with the data for the MAC
subgroup considered for this analysis) [20, 21], and one in-
vestigated nodular/bronchiectatic MAC lung disease [18].
Three studies focused on newly-diagnosed MAC lung dis-
ease [13, 14, 21]. Two of the included studies covered
NTM-PD, however the majority of the patients in these
studies were diagnosed with MAC lung disease [22, 23].
Mortality rates in the identified studies
The five-year all-cause mortality data from each study,
including the ranges and pooled estimate, are shown in
Fig. 2a. The mortality in the studies ranged from 10.0%
(95% CI 21.5–58.4%) to 48.0% (95% CI 33.1–62.9%).
Pooling data from all 17 data sets using a random effects
model, the overall estimate of five-year all-cause mortal-
ity was 27% (95% CI 21.3–33.0%). The I2 statistic was
96% and the Q-statistic was 365.1, indicating a high level
of study heterogeneity. This is also demonstrated in a
funnel plot of data from the selected studies (Fig. 2b).
MAC-related and all-cause mortality
The proportion of all MAC-attributable deaths was
reported by nine studies, and these data are shown in
Fig. 3a. MAC-related five-year all-cause mortality varied
between 5% [25] and 42% [16]. Predictors of all-cause
mortality are listed in Table 2. Several factors appeared
to be consistent across studies. These include male sex
[13, 16, 18–21, 24], presence of comorbidities [13–17,
19–21, 23], and advanced patient age [13, 16, 18, 20–
22, 24]. Predictors of better outcome include surgical
treatment [12] and nodular or bronchiectatic disease [15].
Two studies examined the relationship between nodu-
lar/bronchiectatic and fibrocavitary MAC lung disease
and MAC-related mortality [13, 18]. Both found that pa-
tients with fibrocavitary disease had increased five-year
MAC-related mortality compared with patients with
nodular/bronchiectatic disease (Fig. 3b). One study also
analysed the relationship between radiologic types of
MAC lung disease and all-cause five-year mortality [13].
This demonstrated that patients with fibrocavitary dis-
ease have a substantially greater risk of death compared
with nodular disease (Fig. 3c).
Fig. 1 Flow chart describing the selection of studies and data sets included in the analysis.*Three of the identified publications contained data sets for
two cohorts of patients, and these are considered separately here. MAC, Mycobacterium avium complex; NTM, nontuberculous mycobacterium
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Effect of study region on five-year mortality
We performed a sensitivity analysis using the geographic
region in which the selected studies were conducted
(Additional file 1: Table S1). The analysis demonstrated
that patients in Asian studies tended to have a lower
five-year mortality (19, 95% CI 14–23%) compared with
Europe (35, 95% CI 27–43%) and North America (33,
95% CI 32–35%).
Discussion
The studies identified in this systematic review show
that, in general, patients with MAC lung disease are at a
high risk of death following their diagnosis, with a
pooled estimate of five-year all-cause mortality of 27%.
In line with previous reports [9], we found there to be
considerable heterogeneity between studies, with an I2
value of 96% and Q-statistic of 365.1.
Several publications have demonstrated the incremen-
tal impact of NTM infection on patient mortality.
Adjemian and colleagues found that US patients aged
over 65 with NTM-PD within a nationally-representative
sample were 40% more likely to die during the study
period (1997–2007) than patients without NTM-PD
[26]. Recent work from Ontario, Canada, also reported
an increased mortality in patients with MAC lung
disease compared with a matched control group (HR =
1.57, 95% CI 1.48–1.66, P < 0.0001) [21]. Here, the mor-
tality was 33.3% in cases versus 21.5% in controls. Diel
et al. identified an even greater mortality risk (HR 3.64,
95% CI 2.28–5.77) and a mortality after 39 months
follow-up of 22.4% for NTM-PD patients versus 6.0% for
control patients [27]. These studies indicate that NTM-
PD increases mortality risk at a population level,
independent of underlying comorbidities.
Although predictors of mortality varied between
studies, some common features were observed. A worse
prognosis was noted with male sex, comorbidities (e.g.
coexisting lung disease) and the presence of fibrocavitary
disease. The latter was found to be associated with
increased MAC-related mortality rate in two studies
[13, 18], and in one, all-cause mortality [13]. This is
in line with results from Fleshner and colleagues who
identified fibrocavitary disease as a predictor of mortality
in NTM-PD after controlling for possible confounders
(adjusted hazard ratio [aHR] 3.3, 95% CI 1.3–8.3) [28].
Fleshner and colleagues also documented pulmonary
hypertension as a risk factor for mortality (aHR 2.1, 95%
CI 0.9–5.1), although this was not significant following
adjustment for fibrocavitary disease; importantly, individ-
ual NTM species were not significantly associated with
mortality, suggesting similar risks for each NTM species
identified in the study [28].
Relatively few studies have explored differences in
mortality between cases with confirmed ATS/IDSA dis-
ease criteria against those with NTM isolation only.
From our list of identified studies, Marras and colleagues
found that mortality rates were higher among patients
from Ontario who fulfilled the ATS/IDSA disease
criteria compared with those who had NTM isolation
only (HR = 1.16, 95% CI 1.09–1.24) [21]. Similarly, five-
year age-adjusted mortality rates were slightly higher for
patients meeting (28.7/1000) versus not meeting (23.4/
1000) ATS/IDSA criteria, respectively, in the report by
Novosad identified in our analysis [23]. Andréjak and
colleagues noted a similar prognosis in Danish patients
with confirmed NTM-PD (57% of whom had MAC
isolation) compared with those with NTM isolation only
(HR 1.15, 95% CI 0.90–1.51) [20]. Thus, MAC lung
disease fulfilling ATS/IDSA criteria is associated with a
a
b
Fig. 2 Analysis of five-year mortality in selected data sets. a Forest
plot of five-year all-cause mortality rates in the identified data sets.
Results are plotted ± 95% confidence interval (CI). b Funnel plot of
five-year all-cause mortality versus standard error from selected data
sets. BTS; The Research Committee of the British Thoracic Society
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worse outcome. However, all patients with disease con-
sidered bad enough to be recorded by investigators, and
hence included in studies, are at some increased risk of
death.
Furthermore, whereas all-cause mortality is an object-
ive measure, the proportion of deaths attributed to
MAC lung infection depends largely on how clinicians
determine the cause of death. This may be unclear, par-
ticularly in long-term follow up studies where underlying
comorbidities may progress; it a pertinent issue in MAC
lung disease as many patients are elderly and often have
a number of comorbidities [2, 29]. Thus, the impact of
MAC lung disease on mortality at a population level is
more appropriately reflected in studies using matched
control groups. As shown above, the three studies where
MAC lung disease cases were matched with appropriate
controls consistently showed an increased risk of mortal-
ity for patients with NTM-PD or MAC-PD [21, 26, 27].
Our sensitivity analysis identified a lower mortality
rate in Asian studies, particularly those from Japan. A
similar trend has previously been observed [30]. This
may be driven, in part, by the relatively high proportion
of nodular/bronchiectatic disease in Japanese studies
[15], which most reports suggest has a better outcome.
The present study has several limitations. We were
keen to include a range of studies reflecting the
published literature and so did not use a complex set of
stringent-pre-specified criteria. Thus, our analysis is in-
fluenced by the design of the selected studies. Specific-
ally, only two prospective studies (including three data
sets) are included in our analysis [24, 25]. This is chal-
lenging for the field as a whole, and further prospective
studies of mortality in MAC-PD patients, which could
support identification of additional prognostic factors,
are warranted.
Furthermore, we could not account for the potential
effects of patient immunosuppression (e.g. HIV) or het-
erogeneity of treatment regimens between studies as the
selected studies did not report outcomes for different
subgroups. The studies we have identified cover a wide
time period (1973–2017) and thus may be influenced by
potential variability in NTM diagnosis and treatment
over the 44 year period.
A previous meta-analysis of treatment success rates in
patients with MAC-PD and MAC-non-PD (the latter in-
cluding disseminated disease) also found considerable
treatment outcome heterogeneity for patients with MAC
(I2 > 70%, p < 0.05 for all treatment outcomes) [9]. The
authors suggested that this may be due to inconsistency
among treatment protocols and in the reporting of key
patient and study characteristics [9], preventing
identification of clear factors related to treatment
a
b c
Fig. 3 MAC-related five-year mortality and cavitary disease in selected data sets. a The proportion of all deaths related to MAC lung disease in
the identified data sets. b Fibrocavitary disease and MAC-related five-year mortality. Black bars indicate fibrocavitary disease, grey bars indicate
nodular/bronchiectatic disease. c Fibrocavitary disease and all-cause five-year mortality. Black bars indicate fibrocavitary disease, grey bars indicate
nodular/bronchiectatic disease
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success. However, unlike our study, the authors did not
distinguish between MAC-PD and MAC-non-PD.
It is important to note that, as many reported studies
are frequently based on population-level data (for
example, [21]), they can contain limited clinical informa-
tion. This inevitably means that one must be careful to
not over-interpret their findings.
Most of our selected studies do not explicitly identify
patients with macrolide-resistant pulmonary disease. This
is a concern, as recent work from Korea reported a five-
year mortality of 47.1% (95% CI 24.0–70.1) in patients
with macrolide-resistant MAC [31]. This is much higher
than the pooled estimate from our analysis indicating that
macrolide resistance increases mortality risk, and should
be specifically identified in future studies.
Conclusions
In conclusion, our structured literature review has iden-
tified 17 data sets reporting five-year mortality in
patients with NTM-PD caused by MAC. Most (i.e. ten)
document a five-year mortality rate greater than 25%
[12, 14, 15, 20, 21, 23–25], indicating a poor prognosis
for patients with MAC lung disease and a need for more
effective management of the condition. Substantial
heterogeneity in study characteristics was found, with
male sex, presence of cavitary disease and high comor-
bidity levels predicting worse survival outcomes. Further
prospective studies using appropriately matched controls
may contribute to a better understanding of long-term
survival in MAC-related pulmonary disease.
Additional file
Additional file 1: Search strategies. (DOCX 17 kb)
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Table 2 Predictors of mortality in the identified studies, if any
Data set Negative association
with all-cause
mortality
Positive association
with all-cause
mortality
Reference
1 Surgical treatment Yeager 1973 [12]
2 Male sex
Age ≥ 70 years
Presence of systemic
and/or respiratory
comorbidity
FC disease
BMI < 18.5 kg/m2
Anaemia
Hypoalbuminemia
Erythrocyte sedimentation
rate≥ 50 mm/h
Hayashi 2012 [13]
3 High Charlson
comorbidity index
Presence of FC lesions
Malignancy
Ito 2012 [14]
4 NB disease FC disease
FC + NB disease
Usual interstitial
pneumonia
Emphysema
Other lung disease
Yamakawa 2013 [15]
5 Prior tuberculosis
Bronchiectasis
Asthma
Male sex
Older age
Chronic obstructive
pulmonary disease
Interstitial lung
disease
Lung cancer
HIV infection
Cystic fibrosis
Bone marrow transplant
Morimoto 2014 [16]
6 Chronic pulmonary
aspergillosis
Cavitation
Emphysema
Zoumot 2014 [17]
7 Male sex
Age ≥ 70 years
BMI < 18.5 kg/m2
Absence of bloody
sputum
hypoalbuminaemia
Erythrocyte
sedimentation rate >
40 mm/h
Gochi 2015 [18]
8,9 Male sex
Age ≥ 70 years
Malignancy, including
lung cancer
BMI < 18.5 kg/m2
Lymphocyte count <
1000/μl
FC disease
Kumagai 2017 [19]a
10 Male sex
Age ≥ 65 years
High comorbidity level
Positive smear
Andréjak 2010 [20]
11 NTM-PD with
multiple
species of NTM
isolated
Male sex
Increasing age
Comorbid conditions
Marras 2017 [21]
12 Older age
Low BMI
Pneumonectomy
Remnant cavitary lesions
following pulmonary
resection
Asakura 2017 [22]a
13,14 Lung cancer Novosad 2017 [23]a
Table 2 Predictors of mortality in the identified studies, if any
(Continued)
Data set Negative association
with all-cause
mortality
Positive association
with all-cause
mortality
Reference
15 Increasing age
Male sex
Involvement of
> 1 lung zone
Low initial body
weight
Research Committee
of the British Thoracic
Society 2002 [24]
16,17 Adding clarithromycin
vs. ciprofloxacin to
rifampicin and
ethambutol therapy
regimen
Jenkins 2008 [25]
BMI body mass index, FC fibrocavitary disease, HIV human immunodeficiency
virus, NB nodular bronchiectatic disease, NTM nontuberculous mycobacteria,
NTM-PD nontuberculous mycobacterial pulmonary disease
aFactors found to be significant by multivariate analysis are listed
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fibrosis; CI: Confidence interval; COPD: Chronic obstructive pulmonary
disease; MAC: Mycobacterium avium complex; NTM: Nontuberculous
mycobacterium; NTM-PD: Nontuberculous mycobacteria pulmonary disease;
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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